Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

BACKGROUND: A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between caffeine and cardiovascular events is of clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Am Heart Assoc
Hauptverfasser: Furtado, Remo H. M., Venkateswaran, Ramkumar V., Nicolau, Jose C., Gurmu, Yared, Bhatt, Deepak L., Storey, Robert F., Steg, P. Gabriel, Magnani, Giuglia, Goto, Shinya, Dellborg, Mikael, Kamensky, Gabriel, Isaza, Daniel, Aylward, Philip, Johanson, Per, Bonaca, Marc P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7660882/
https://ncbi.nlm.nih.gov/pubmed/32410485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.015785
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge